论文部分内容阅读
目的:对幽门螺杆菌(Hp)感染的3种药物治疗方案进行药物经济学评价。方法:A组用兰索拉唑30mg+呋喃唑酮100 mg+克拉霉素250 mg,bid×7d+兰索拉唑30 mg,qd×14 d;B组用雷贝拉唑10 mg+呋喃唑酮100mg+克拉霉素250 mg,bid×7 d+雷贝拉唑10 mg,qd×14 d;C组用奥美拉唑20 mg+呋喃唑酮100 mg+克拉霉素250mg,bid×7 d+奥美拉唑20 mg,qd×14 d。用成本效果分析法对3种方案进行分析。结果:A,B,C 3种方案的成本效果比(C/E)分别为18.60,20.04,16.30。结论:方案C是3种方案中最经济、合理的方案。
Objective: To evaluate the pharmacoeconomic evaluation of three drug regimens of Helicobacter pylori (Hp) infection. Methods: Group A was treated with lansoprazole 30 mg + furazolidone 100 mg + clarithromycin 250 mg, bid × 7 d + lansoprazole 30 mg, qd × 14 d, group B with rabeprazole 10 mg + furazolidone 100 mg + clarithromycin 250 mg , bid × 7 d + rabeprazole 10 mg, qd × 14 d; group C with omeprazole 20 mg + furazolidone 100 mg + clarithromycin 250 mg, bid × 7 d + omeprazole 20 mg, qd × 14 d. Cost-effectiveness analysis of the three programs were analyzed. Results: The cost-effectiveness ratios (C / E) of A, B and C were 18.60,20.04 and 16.30 respectively. Conclusion: Plan C is the most economical and reasonable plan among the three plans.